Nature Biotechnology Study Reveals That Tempus’ xT Platform Increases Cancer Patients’ Personalized Therapeutic Opportunities
September 30, 2019 11:00 ET
|
Tempus
CHICAGO, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today published a...
European Research Initiative Adopts PacBio Sequel II System to Solve Rare Diseases
September 05, 2019 07:30 ET
|
Pacific Biosciences of California, Inc.
MENLO PARK, Calif., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes,...
Fluidigm and the Icahn School of Medicine at Mount Sinai Collaborate on Landmark Single-Cell Study of the Human Epigenome
August 27, 2019 08:30 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Tempus Expands Leadership Team With the Appointment of Joel Dudley, PhD, as Senior Vice President of Research
August 22, 2019 12:00 ET
|
Tempus
CHICAGO, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Tempus, a technology company advancing precision medicine through the collection and analysis of molecular and clinical data at scale, announces the...
Fluidigm to Participate in Upcoming Health Care Investor Conferences
August 20, 2019 16:05 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Aug. 20, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Emendo Biotherapeutics Achieves Milestone of Collaboration with Takeda for its OMNI Nuclease Program
August 20, 2019 09:00 ET
|
Emendo Biotherapeutics
NEW YORK, Aug. 20, 2019 (GLOBE NEWSWIRE) -- Emendo Biotherapeutics today announced that the company achieved the first milestone as laid out in the agreements with Takeda Pharmaceutical Company...
CORRECTING and REPLACING - Fluidigm Announces Second Quarter 2019 Financial Results
August 02, 2019 00:41 ET
|
Fluidigm Corporation
Second Quarter Revenue Increased 7 Percent to $28.2 Million Mass Cytometry Revenue Growth of 28 Percent in Second Quarter Expansion of Mass Cytometry Products with New Metal Markers and Imaging Mass...
Fluidigm Announces Second Quarter 2019 Financial Results
August 01, 2019 16:05 ET
|
Fluidigm Corporation
Second Quarter Revenue Increased 7 Percent to $28.2 Million Mass Cytometry Revenue Growth of 28 Percent in Second Quarter Expansion of Mass Cytometry Products with New Metal Markers and Imaging Mass...
Fluidigm to Automate RNA Sequencing Library Preparation Using Microfluidics Technology
August 01, 2019 08:30 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
MaRS Innovation Launches New Drug Discovery Program Targeting Rare and Disabling Developmental Disorder
July 15, 2019 07:00 ET
|
MaRS Innovation
Toronto, ON, July 15, 2019 (GLOBE NEWSWIRE) -- MaRS Innovation announced today that it is partnering with Dr. James Eubanks at the University Health Network (UHN) to develop a new treatment for Rett...